KR20190133216A - 비흑색종 피부암(nmsc)의 예방 및 치료 - Google Patents

비흑색종 피부암(nmsc)의 예방 및 치료 Download PDF

Info

Publication number
KR20190133216A
KR20190133216A KR1020197031641A KR20197031641A KR20190133216A KR 20190133216 A KR20190133216 A KR 20190133216A KR 1020197031641 A KR1020197031641 A KR 1020197031641A KR 20197031641 A KR20197031641 A KR 20197031641A KR 20190133216 A KR20190133216 A KR 20190133216A
Authority
KR
South Korea
Prior art keywords
mrna
ifn
utr
human
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031641A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 맨틀러
아힘 슈네베르거
발터 슈미트
프랭크 마트너
Original Assignee
아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게 filed Critical 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Publication of KR20190133216A publication Critical patent/KR20190133216A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
KR1020197031641A 2017-03-31 2018-03-29 비흑색종 피부암(nmsc)의 예방 및 치료 Ceased KR20190133216A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162 2017-11-06
EP17200162.0 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (1)

Publication Number Publication Date
KR20190133216A true KR20190133216A (ko) 2019-12-02

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031641A Ceased KR20190133216A (ko) 2017-03-31 2018-03-29 비흑색종 피부암(nmsc)의 예방 및 치료

Country Status (8)

Country Link
US (1) US20200038487A1 (https=)
EP (2) EP4019037A1 (https=)
JP (1) JP7264867B2 (https=)
KR (1) KR20190133216A (https=)
CN (1) CN110636854A (https=)
AU (1) AU2018246292A1 (https=)
CA (1) CA3057768A1 (https=)
WO (1) WO2018178215A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
WO2020227625A1 (en) 2019-05-08 2020-11-12 Laura Hansen 14-3-3 targeting peptides for cancer treatment
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
CA1295243C (en) * 1986-05-27 1992-02-04 Daniel J. Tanner Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
EP0351974A1 (en) 1988-07-05 1990-01-24 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant DNA human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
BR9712362A (pt) * 1996-10-18 1999-08-31 Canji Inc Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
RU2262510C9 (ru) 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
CA2976376A1 (en) * 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Also Published As

Publication number Publication date
EP3600379A1 (en) 2020-02-05
CN110636854A (zh) 2019-12-31
AU2018246292A1 (en) 2019-10-10
EP3600379B1 (en) 2022-12-21
JP7264867B2 (ja) 2023-04-25
EP4019037A1 (en) 2022-06-29
CA3057768A1 (en) 2018-10-04
JP2020515644A (ja) 2020-05-28
WO2018178215A1 (en) 2018-10-04
US20200038487A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
KR20190133216A (ko) 비흑색종 피부암(nmsc)의 예방 및 치료
CN109476718B (zh) 编码免疫调节多肽的mrna的组合及其用途
ES2622958T3 (es) ARNip frente a Cbl-b combinado con citocinas e interferones en el tratamiento de cáncer
CN103003427B (zh) 具有佐剂活性的新型核酸及其应用
US20200369738A1 (en) Treatment of Local Skin Hypotrophy Conditions
US12343420B2 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
JP2003525222A (ja) Ｉｌ−１２をコードする核酸分子の腫瘍内投与
CN113769063B (zh) 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用
JP2015096073A (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
WO2015172659A1 (zh) Il-17在提高间充质干细胞免疫抑制功能中的应用
Liu et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
JPWO2009069668A1 (ja) 悪性黒色腫抗原の発現上昇剤及びその用途
AU2016243027A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
WO2023240225A1 (en) Constitutively active polymeric sting mimics for antitumor immunity
JP2024509084A (ja) 核酸ベクター及び使用方法
CN110551197B (zh) 一种微肽及癌症治疗的药物
JP5789927B2 (ja) 放射線照射コラーゲン様ペプチドを用いた核酸導入法
CN117280029A (zh) 核酸载体和使用方法
Cao Intrapericardial Delivery of a ROS-Responsive Hydrogel Encapsulating FAP-Specific CAR-T Cells for Localized Treatment of Cardiac Fibrosis
KR20250109232A (ko) 포유류에서 엘라스틴 신생합성을 유도하기 위한 코돈 최적화 올리고뉴클레오티드
JP2017200914A (ja) ケモカインｃｘｃｌ１４を利用した自然免疫活性化アジュバント
WO2026048718A1 (ja) Ｐｓａｐを標的とした二本鎖ｒｎａ及びその利用
CA2878758A1 (en) Method of treating wounds with penostin and/or ccn2
CN119101650A (zh) 一种增强型中性粒细胞药物的构建及应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230329

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231005

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231005

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I